Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aloxi Sees Share Gains, Volume Drop In First Month Under Medicare ASP

Executive Summary

MGI Pharma's anti-emetic Aloxi (palonosetron) gained market share in the first month of average sales price-based reimbursement despite a drop in prescription volume for the class
Advertisement

Related Content

Specialty Pharmacies Adopting PBM Formulary Management Practices
Specialty Pharmacies Adopting PBM Formulary Management Practices
MGI Saforis NDA To Be Based On Single Phase III Trial; Filing Planned For Q3
MGI Saforis NDA To Be Based On Single Phase III Trial; Filing Planned For Q3
Oncologists Embrace Part B Demo, Amgen Says; Big Test In Two Months
Oncologists Embrace Part B Demo, Amgen Says; Big Test In Two Months
Medicare Part B Demo, Coding Changes Will Stabilize Oncology Rx Market
Aloxi Payment Cut By One-Third Under Medicare ASP Rule

Topics

Advertisement
UsernamePublicRestriction

Register

PS045356

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel